Evidence map›Paper›PMID 28186707›Full record

ArticleStem cells translational medicine2017

Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First-in-Man Study.

Daniel C Chambers, Debra Enever, Sharon Lawrence, Marian J Sturm, Richard Herrmann, Stephanie Yerkovich, Michael Musk, Peter M A Hopkins

Open access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Donor-derived cell-free DNA associated with increased risk of chronic lung allograft dysfunction and mortality: Are absolute levels better than percentage?The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2026
    Observational
  7. Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Mesenchymal Stromal Cell Therapy in Lung Transplantation.Bioengineering (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Daniel C ChambersSchool of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Debra EneverQueensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Sharon LawrenceWestern Australian Lung Transplant Program, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Marian J SturmDepartment of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia.
Richard HerrmannDepartment of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia, Australia.
Stephanie YerkovichSchool of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Michael MuskWestern Australian Lung Transplant Program, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Peter M A HopkinsSchool of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
University of Queensland · AUFiona Stanley Hospital · AUUniversity of Western Australia · AUPrince Charles Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lung transplant rejection (termed chronic lung allograft dysfunction [CLAD]) is the main impediment to long-term survival after lung transplantation. Bone marrow-derived mesenchymal stromal cells (MSCs) represent an attractive cell therapy in inflammatory diseases, including organ rejection, given their relative immune privilege and immunosuppressive and tolerogenic properties. Preclinical studies in models of obliterative bronchiolitis and human trials in graft versus host disease and renal transplantation suggest potential efficacy in CLAD. The purpose of this phase 1, single-arm study was to explore the feasibility and safety of intravenous delivery of allogeneic MSCs to patients with advanced CLAD. MSCs from unrelated donors were isolated from bone marrow, expanded and cryopreserved in a GMP-compliant facility. Patients had deteriorating CLAD and were bronchiolitis obliterans (BOS) grade ≥ 2 or grade 1 with risk factors for rapid progression. MSCs (2 x 10

Indexed as

AdultBone Marrow CellsCell- and Tissue-Based TherapyFemaleGraft RejectionGraft vs Host DiseaseHumansLung TransplantationMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiddle AgedCell- and tissue-based therapyClinical trialGraft rejectionLung transplantationMesenchymal stromal cellsPhase 1

Identifiers

PMID28186707
PMCPMC5442848
OpenAlexW2585581200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.